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Background. Current guidelines recommend screening all people living with human immunodeficiency virus (PLHIV) who 
have a CD4 count ≤100 cells/µL for cryptococcal antigen (CrAg) to identify those patients who could benefit from preemptive flu-
conazole treatment prior to the onset of meningitis. We conducted a systematic review to assess the prevalence of CrAg positivity at 
different CD4 cell counts.
Methods. We searched 4 databases and abstracts from 3 conferences up to 1 September 2017 for studies reporting prevalence of 
CrAg positivity according to CD4 cell count strata. Prevalence estimates were pooled using random effects models.
Results. Sixty studies met our inclusion criteria. The pooled prevalence of cryptococcal antigenemia was 6.5% (95% confidence 
interval [CI], 5.7%–7.3%; 54 studies) among patients with CD4 count ≤100 cells/µL and 2.0% (95% CI, 1.2%–2.7%; 21 studies) 
among patients with CD4 count 101–200 cells/µL. Twenty-one studies provided sufficient information to compare CrAg prevalence 
per strata; overall, 18.6% (95% CI, 15.4%–22.2%) of the CrAg-positive cases identified at ≤200 cells/µL (n = 11 823) were identified 
among individuals with a CD4 count 101–200 cells/µL. CrAg prevalence was higher among inpatients (9.8% [95% CI, 4.0%–15.5%]) 
compared with outpatients (6.3% [95% CI, 5.3%–7.4%]).
Conclusions. The findings of this review support current recommendations to screen all PLHIV who have a CD4 count ≤100 
cells/µL for CrAg and suggest that screening may be considered at CD4 cell count ≤200 cells/µL.
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The burden of cryptococcal meningitis among people living 
with human immunodeficiency virus (PLHIV) remains sub-
stantial despite scale-up of antiretroviral therapy (ART) [1]. 
A recent review estimated that globally there were 223 100 inci-
dent cryptococcal meningitis cases (with 73% of the cases occur-
ring in sub-Saharan Africa), resulting in almost 200 000 deaths 
in 2014 [2].
Current World Health Organization (WHO) guidelines rec-
ommend screening all PLHIV who have a CD4 count ≤100 cells/
µL for cryptococcal antigen (CrAg) to identify those patients 
with cryptococcal disease  who could benefit from preemptive 
fluconazole treatment prior to the onset of meningitis. CrAg may 
be detected several weeks before clinical features of cryptococcal 
meningitis become apparent [3]. Providing preemptive flucona-
zole treatment during this period of antigenemia prior to onset 
of meningitis symptoms has been found to be life saving and cost 
effective across a range of settings [4–7]. Some countries have 
chosen higher CD4 cell count thresholds for their cryptococcal 
screening guidelines: Ethiopia has adopted a cutoff of 150 cells/
µL, whereas in Rwanda CrAg screening is done at a CD4 count of 
≤200 cells/µL.
Recent WHO guidelines advise that a CD4 threshold of 
≤200 cells/µL be used to define patients who have advanced 
HIV disease [8], and studies have suggested there may be 
benefit to CrAg screening among PLHIV using a higher 
CD4 count threshold of ≤200 cells/µL to identify additional 
numbers of PLHIV at risk of developing cryptococcal men-
ingitis [9–12]. The current recommended threshold for CrAg 
screening at CD4 count ≤100 cells/µL is based on evidence 
from a limited number of studies, and there may be benefits 
to simplifying screening strategies to target all patients with 
advanced human immunodeficiency virus (HIV) disease. We 
conducted a systematic review to assess prevalence of CrAg 
positivity at CD4 count ≤100 cells/µL compared to 101–200 
cells/µL across a range of settings.
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METHODS
Search Strategy and Selection Criteria
This systematic review was conducted according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines [13]. Using a study protocol (avail-
able from the corresponding author), we sought randomized 
and quasi-randomized controlled trials, and comparative and 
noncomparative observational studies reporting prevalence of 
CrAg positivity according to CD4 cell count strata.
Using a broad search strategy combining terms for HIV in-
fection and CrAg screening, 3 investigators (N. F., Z. S., C. M.), 
working independently and in duplicate, screened titles and 
abstracts from Medline via PubMed, Embase, and the Cochrane 
library, from inception to 1 September 2017. Abstracts from 
the International AIDS Society conferences, the Conferences 
on Retroviruses and Opportunistic Infections, and the 
International Conference on Cryptococcus and Cryptococcosis 
were also screened from 2012 to 2017 to identify studies that 
have been recently completed but not yet published in full. 
Database searches were supplemented by screening bibliogra-
phies of review articles and all included full-text articles. The 
same investigators scanned all abstracts and full-text articles 
and achieved consensus on final study inclusions.
Reasons for exclusions included studies using samples other 
than serum, plasma, or whole blood. If studies included patients 
with a history of cryptococcal disease or overt clinical menin-
gitis, then these patients were excluded from the study denomi-
nators and numerators included in this review; where it was not 
possible to remove these patients from the study population, the 
studies were only included if <10% of patients met these crite-
ria. No language or geographical restrictions were applied.
Data Extraction
The same 3 investigators extracted data following a predefined 
protocol and using a standardized and piloted extraction form. 
Study characteristics included design, year, population, loca-
tion, ART status, CrAg positivity by CD4 cell count stratum, and 
active tuberculosis (TB) infection. Where reported, outcomes for 
CrAg-positive patients who received or did not receive flucona-
zole were also extracted. Additional information was extracted 
to inform an assessment of risk of bias and the certainty of the 
evidence using the Grading of Recommendations Assessment, 
Development, and Evaluation (GRADE) approach [14].
Statistical Analysis
To estimate CrAg prevalence by CD4 cell count stratum, point esti-
mates and corresponding 95% confidence intervals (CIs) were cal-
culated and data were pooled using random-effects meta-analysis 
[15], following data transformation [16, 17]. The same approach was 
used to summarize clinical outcomes among CrAg-positive patients 
started and not started on fluconazole. Prevalence odds ratios were 
calculated to compare diagnostic yield by CD4 cell count strata (≤100 
vs 101–200 cells/µL) using random effects models. Heterogeneity 
was assessed though visual inspection of forest plots and subgroup 
analyses to examine potential differences by geographical region, 
clinical setting, type of CrAg screening test used, and sample type. 
We analyzed all data with Stata version 13.0 software.
RESULTS
Characteristics of Included Studies
From an initial screen of 540 titles, 60 studies were included in 
this review (Figure 1) [6, 9–12, 18–70]. Among these, 40 were 
prospective studies (including one randomized trial) and 20 
were retrospective studies; 42 studies were published in full, 
16 were abstracts, and additional unpublished data were pro-
vided from Médecins Sans Frontières (MSF)–supported HIV 
programs in Kenya and the Democratic Republic of Congo. 
Data came from 28 countries, with the majority of studies (41) 
carried out in Africa. Median age of patients ranged from 30 
to 47 years, and the proportion who were female ranged from 
20% to 74%. Date of study end ranged from 2013–2017 (me-
dian 2014). Most studies (41 studies [66%]) used sera as the 
sample type and a lateral flow assay (34 studies [57%]). Thirty-
two studies reported that all patients screened (n = 18 657) were 
ART naive, while 16 studies (n = 6950) reported that a propor-
tion of patients were ART experienced (median, 41.7% [inter-
quartile range], 18.4%–72.4%) (Supplementary Appendix).
Risk of bias overall was assessed as being moderate 
(Supplementary Appendix). The majority of studies used a pro-
spective study design (40 studies), were published in full (42 
studies), and had <10% missing data (52 studies). Only 2 studies 
reported blinding of investigators and only 3 studies reported 
random sampling of patients. In subgroup analysis, none of 
these risk of bias indicators influenced CrAg prevalence esti-
mates. Overall, the certainty of evidence was rated as moderate.
Prevalence of Cryptococcal Antigenemia
The pooled prevalence of cryptococcal antigenemia as deter-
mined by CrAg positivity was 6.5% (95% CI, 5.7%–7.3%; 54 
studies) among patients with CD4 count ≤100 cells/µL and 
2.0% (95% CI, 1.2%–2.7%; 21 studies) among patients with 
CD4 count 101–200 cells/µL (Figures 2 and 3).
Twenty-one studies provided sufficient information to com-
pare CrAg prevalence at CD4 count ≤100 cells/µL vs 101–200 
cells/µL within each study. The prevalence odds ratio compar-
ing CD4 count ≤100 cells/µL and CD4 count 101–200 cells/µL 
was 2.5 (95% CI, 1.9–3.3) (Figure 4). Overall, 18.6% (95% CI, 
15.4%–22.2%) of the total CrAg-positive cases identified in this 
sample of patients with CD4 ≤200 cells/µL (n = 11 823) were 
among individuals with a CD4 count 101–200 cells/µL.
Among patients with CD4 count ≤100 cells/µL, CrAg posi-
tivity ranged from 0.3% (95% CI, 0.3%–2.5%) in Iran to 22.8% 
(95% CI, 17%–29.2%) in DRC (MSF, unpublished data). In sub-
group analysis, there was substantial variability by geographical 
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region, with CrAg prevalence highest in the Africa Region 
(6.7% [95% CI, 5.7%–7.6%]), the South-East Asia Region (6.9% 
[95% CI, 4.4%–9.5%]), and the Western Pacific Region (13.3% 
[95% CI, 7.4%–19.1%]). CrAg prevalence was also higher 
among inpatients (9.8% [95% CI, 4.0%–15.5%]) than outpa-
tients (6.3% [95% CI, 5.3%–7.4%]). A  higher prevalence was 
also seen in studies that used nonfrozen samples (7.8% [95% 
CI, 6.5%–9.0%]) rather than stored samples (4.7% [95% CI, 
3.8%–5.5%]). CrAg prevalence was similar comparing studies 
that only enrolled ART-naive patients and those that included 
both ART-naive and ART-experienced patients (Figure 5).
Clinical Outcomes
Nineteen studies reported outcomes among 353 CrAg-positive, 
asymptomatic PLHIV who were started on fluconazole proph-
ylaxis [9, 11, 19, 21, 24–27, 31, 38, 42, 52, 54, 55, 60–62, 64, 70], 
with clinical outcomes from one study [19] reported in a sep-
arate report [71]. Median follow-up time was 9 months (inter-
quartile range, 6–12  months). Of these, 34 (9.6%) of patients 
had died, among whom none were documented to have died 
of cryptococcal meningitis. Nineteen (5.4%) developed inci-
dent cryptococcal disease. Fourteen studies reported outcomes 
among 118 CrAg-positive, asymptomatic PLHIV who were not 
started on fluconazole prophylaxis [9, 11, 12, 20, 21, 25–27, 31, 
38, 41, 42, 70, 71]. Of these, 22 (18.6%) had died, among whom 
2 were documented to have died of cryptococcal meningitis; 3 
others developed incident cryptococcal disease.
Thirteen studies reported the prevalence of TB disease among 
patients who were CrAg positive, using different TB screening 
approaches [9, 11, 19–22, 26, 28, 33, 41, 46, 57, 72]. Among 234 
patients screened CrAg positive, 45 also were diagnosed with 
TB, giving an overall prevalence of coexistent disease of 19.2% 
(95% CI, 14.4%–24.9%).
DISCUSSION
Cryptococcal meningitis remains an important cause of morbidity 
and mortality among people with HIV, despite major improvements 
in access to HIV testing and treatment services [2]. This is largely 
explained by an enduring burden of advanced HIV disease, either 
because people present late for diagnosis and care or, increasingly, 
because PLHIV interrupt ART for a period during which time their 
CD4 cell count drops, placing them at risk of major opportunistic 
infections including cryptococcal meningitis [73].
This review estimated prevalence from available studies, by 
country and region, and found a high prevalence of CrAg positiv-
ity among people with advanced HIV disease that, consistent with 
expectations, was higher among those with a lower CD4 cell count. 
Figure 1. Study selection process. Abbreviation: HIV, human immunodeficiency virus.
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These findings support current guidance to screen all individuals 
presenting for care with a CD4 count ≤100 cells/µL. Prevalence 
at CD4 count ≤100 cells/µL was highest in the Africa, South-East 
Asia, and Western Pacific regions. The finding that one fifth of 
CrAg-positive patients were also found to have TB supports the 
inclusion of CrAg and TB testing as part of a package to manage 
advanced HIV disease.
This review further suggests that there may be additional bene-
fit to screening individuals at CD4 cell count up to 200 cells/µL, 
depending on availability of resources and considering the practi-
cal advantage of providing the same package of care to all patients 
with advanced HIV disease within a public health approach. 
Almost one-fifth of CrAg-positive cases identified at CD4 count 
≤200 cells/µL are identified at CD4 between 101 and 200 cells/
µL. Cost-effectiveness analyses have so far focused on the benefit 
of CrAg screening at CD4 count ≤100 cells/µL, and there is some 
evidence of benefit down to a prevalence of 0.6% of cryptococcal 
antigenemia [4]. Further cost-effectiveness research is needed to 
assess the value of screening at a higher CD4 cell count threshold 
of 200 cells/µL, which has already been suggested to be cost sav-
ing if carried out in inpatient settings [9].
There is a growing evidence base supporting the clinical 
benefit and cost effectiveness of CrAg screening in combin-
ation with enhanced ART adherence and delivery interven-
tions. A trial conducted in the United Republic of Tanzania 
and Zambia randomized 1999 ART-naive adults living with 
HIV with a CD4 count <200 cells/µL to receive enhanced 
clinic-based care with CrAg screening and preemptive 
antifungal treatment for those who were CrAg positive; 
importantly, additional community support including ART 
delivery and adherence counseling was provided to the 
intervention group. The trial reported a 28% reduction in 
mortality (13% vs 18%) among people receiving the inter-
vention compared to standard care [52]. In an unpublished 
post hoc analysis, a statistically significant mortality reduc-
tion was found in both people with a CD4 count <100 cells/
Figure 2. Prevalence of CrAg positivity among patients with CD4 count ≤100 cells/μL. Abbreviations: CI, confidence interval; CrAg, cryptococcal antigen; DRC, Democratic 
Republic of the Congo; IAS, International AIDS Society; MSF, Médecins Sans Frontières.
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Figure  3. Prevalence of CrAg positivity among patients with CD4 count 100–200 cells/μL. Abbreviations: CI, confidence interval; CrAg, cryptococcal antigen; DRC, 
Democratic Republic of the Congo; MSF, Médecins Sans Frontières.
Figure 4. CrAg prevalence odds ratio (CD4 count ≤100 cells/μL vs 100–200 cells/μL). Abbreviations: CI, confidence interval; CrAg, cryptococcal antigen; DRC, Democratic 
Republic of the Congo; MSF, Médecins Sans Frontières.
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µL (mortality rate ratio, 0.75 [95% CI, .58–.95]) and those 
with a CD4 cell count of 101–200 cells/µL (mortality rate 
ratio, 0.56 [95% CI, .32–.97]).
A recent study from South Africa reported the numbers 
of patients starting ART in 2016 at different CD4 cell count 
thresholds using data from the national laboratory database 
[74]. According to this analysis, 128 888 patients (16.8% of the 
total) started ART at a CD4 count ≤100 cells/µL and 123 164 
(16.1%) started at a CD4 count of 101–200 cells/µL. Applying 
the pooled prevalence estimates from this review, 8249 patients 
(95% CI, 7347–9280) would theoretically be identified as being 
CrAg positive at a CD4 screening threshold of 100 cells/µL, 
and an additional 2463 patients (95% CI, 1478–3325) would be 
identified if a threshold of CD4 200 cells/µL were applied.
The majority of studies included in this review were car-
ried out in Africa, and the findings of this review are of 
greatest relevance to settings with a high burden of HIV and 
cryptococcal meningitis. Nevertheless, cryptococcal disease 
remains an important cause of illness and death among peo-
ple with HIV in high-income settings, and the role of CrAg 
screening and preemptive therapy should be considered in 
these settings [48].
Strengths of this review include a broad and inclusive search 
strategy that allowed for the identification of a large number 
of studies for analysis. Heterogeneity was anticipated, and 
explored using standard methods that increased confidence 
in the overall findings. The main limitations to note are the 
limited reporting of important information which may influ-
ence CrAg prevalence, notably ART experience, which was 
missing for one-fifth of studies included in this review, and 
the limited reporting of clinical outcomes. Another limitation 
relates to methodological quality, with a number of studies 
being carried out retrospectively and only 3 studies report-
ing random patient sampling. While methodological quality 
did not appear to importantly influence the prevalence esti-
mates, future studies are encouraged to take steps to improve 
methodological rigor.
This review highlights several directions for research, includ-
ing the cost effectiveness of screening at higher CD4 cell counts 
and the appropriateness and cost effectiveness of screening 
ART-experienced adults and adolescents with low CD4 counts.
In conclusion, the findings of this review support current rec-
ommendations to screen all adults and adolescents who have a 
CD4 count ≤100 cells/µL for CrAg, whether they are ART naive 
or experienced, and provide preemptive fluconazole treatment 
to those testing positive. Consideration should also be given to 
screening at a higher CD4 count of ≤200 cells/µL in settings 
where there are sufficient resources to implement such an 
approach, or where a simplified package of care for advanced 
disease is required based on a unified CD4 threshold.
Figure 5. Factors associated with CrAg positivity at CD4 count ≤100 cells/μL. Abbreviations: ART, antiretroviral therapy; AFRO, Africa Region; AMRO N, North America 
Region; AMRO S, South America Region; CI, confidence interval; CrAg, cryptococcal antigen; EMRO, Mediterranean Region; EURO, Europe Region; SEARO, South-East Asia 
Region; WPRO, Western Pacific Region.
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Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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